First-episode psychosis Mental and Behavioural Disorders Psychosis
Conditions
Interventions
The study is un-blinded and features a 1:1 allocation to the treatment group and the control group.
All 20 participants randomised to the treatment group receive access to My Journey 3
self-monitoring of symptoms and medication adherence
identifying things to do to keep well and setting and tracking personal recovery goals
and relapse prevention and crisis planning. Participants in the treatment group first get access to My Journey 3 on their Smartphone at an app training session with a study researcher and a supporting
Sponsors
Camden & Islington NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Currently on the caseload of an Early Intervention Service and in contact with clinicians 2. Aged 16 or older 3. Have a diagnosis of psychosis 4. Own an Android Smartphone
Exclusion criteria
Exclusion criteria: 1. Lack capacity to provide consent to take part in the study 2. Unable to communicate and understand English sufficiently to understand trial procedures and use the app 3. In the view of their EIS team, pose such a high risk to others that it would be unsafe to conduct research meetings even on NHS premises
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse as indicated by admission to acute care (inpatient wards, crisis resolution teams, crisis houses and acute day services) during the 12-month follow-up period. Data on admissions to acute care during the trial period is collected from patient records at the 12-month follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Social outcomes are measured using The Social Outcomes Index (Priebe, Watzke, Hansson & Burns, 2008) at the study baseline meeting, at a 4-month follow-up meeting and at a 12-month follow-up meeting 2. Mental wellbeing is assessed using The Mental Health Confidence Scale (Carpinello et al., 2000) and The Warwick-Edinburgh Mental Well-Being Scale (NHS Health Scotland, University of Warwick & University of Edinburgh, 2007) at the study baseline meeting, at a 4-month follow-up meeting and at a 12-month follow-up meeting 3. Recovery in psychosis is assessed using The Process of Recovery Questionnaire (Neil et al., 2009) at the study baseline meeting, at a 4-month follow-up meeting and at a 12-month follow-up meeting 4. Quality of life and satisfaction with treatment is assessed using The DIALOG scale (Priebe et al., 2007) at the study baseline meeting, at a 4-month follow-up meeting and at a 12-month follow-up meeting 5. Positive, negative and general psychopathology symptoms are assessed using the PANSS (Kat et al., 1987) at the study baseline meeting, at a 4-month follow-up meeting and at a 12-month follow-up meeting 6. Participants' engagement with Early Intervention Services during the study period is obtained using the Service Engagement Scale (SES; Tait et al., 2002) completed by participants' clinicians at baseline and at the 12-month follow-up. 7. The following patient information is collected from patient records at baseline and one year after entry into the study: 7.1. Current diagnosis 7.2. Current care cluster 7.3. Care plan approach status 8. The usability and acceptability of My Journey 3 for service users and clinicians is assessed from semi-structured qualitative conducted at the 4-month follow-up meeting. | — |
Countries
England, United Kingdom
Contacts
Public ContactThomas Steare
Outcome results
None listed